ANTI-CD3 ANTIBODIES AND METHODS OF USE

• US 20150166661A1
• Filed: 12/17/2014
• Published: 06/18/2015
• Est. Priority Date: 12/17/2013
• Status: Active Grant

• Current Assignee: Genentech, Inc. (Roche Holding AG)
• Original Assignee: Genentech, Inc. (Roche Holding AG)
• Inventors: CHEN, Xiaocheng, DENNIS, Mark S., EBENS, Allen J. Jr., JUNTTILA, Teemu T., KELLEY, Robert F., MATHIEU, Mary A., SUN, Liping L.
• Granted Patent: US 10,174,124 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 39/39558 against tumor tissues, cells, antigens
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/6881 Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/04 : Immunostimulants
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 : Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/04 : Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/08 : Vasodilators for multiple indications
• CPC Class Codes: C07K 16/2809 : against the T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 16/2827 : against B7 molecules, e.g. CD80, CD86
• CPC Class Codes: C07K 16/283 : against Fc-receptors, e.g. CD16, CD32, CD64 CD23 C07K16/2851
• CPC Class Codes: C07K 16/2863 : against receptors for growth factors, growth regulators
• CPC Class Codes: C07K 16/2887 : against CD20
• CPC Class Codes: C07K 16/2896 : against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 16/30 : from tumour cells
• CPC Class Codes: C07K 16/32 : against translation products of oncogenes
• CPC Class Codes: C07K 2317/21 : from primates, e.g. man
• CPC Class Codes: C07K 2317/24 : containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/31 : multispecific
• CPC Class Codes: C07K 2317/33 : Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/34 : Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/522 : CH1 domain
• CPC Class Codes: C07K 2317/524 : CH2 domain
• CPC Class Codes: C07K 2317/526 : CH3 domain
• CPC Class Codes: C07K 2317/54 : F(ab')2
• CPC Class Codes: C07K 2317/55 : Fab or Fab'
• CPC Class Codes: C07K 2317/56 : variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/622 : Single chain antibody (scFv)
• CPC Class Codes: C07K 2317/71 : Decreased effector function due to an Fc-modification
• CPC Class Codes: C07K 2317/73 : Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.

Claims

1. A bispecific antibody that binds to CD20 and CD3, wherein the bispecific antibody comprises an anti-CD20 arm comprising a first binding domain comprising the following six hypervariable regions (HVRs):

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO;

157;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO;

158;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO;

159;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO;

160;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO;

161; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO;

162; and

an anti-CD3 arm comprising a second binding domain comprising the amino acid sequences of any one of the following six HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3, respectively;

SEQ ID NOs;

1-6;

SEQ ID NOs;

7, 8, 181, 10, 11, and 182;

SEQ ID NOs;

23, 183, 25, 26, 27, and 28;

SEQ ID NOs;

31-36;

SEQ ID NOs;

37-42;

SEQ ID NOs;

43-48;

SEQ ID NOs;

49-54;

SEQ ID NOs;

55-60;

SEQ ID NOs;

61-66;

SEQ ID NOs;

67-72;

SEQ ID NOs;

73-78;

SEQ ID NOs;

79-84;

SEQ ID NOs;

85-90;

SEQ ID NOs;

91-96;

SEQ ID NOs;

97-102;

SEQ ID NOs;

103-108;

SEQ ID NOs;

109-114;

SEQ ID NOs;

115-120;

SEQ ID NOs;

121-126;

SEQ ID NOs;

127-132;

SEQ ID NOs;

133-138;

SEQ ID NOs;

139-144;

SEQ ID NOs;

145-150;

SEQ ID NOs;

151-156;

or

SEQ ID NOs 631-636.

2. The bispecific antibody of claim 1, wherein the first binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:

266;

(b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

267;

or (c) a VH domain as in (a) and a VL domain as in (b), and

the second binding domain comprises;

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

184;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

185;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

186;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

187;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

214;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

215;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

216;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

217;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

218;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

219;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

220;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

221;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

222;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

223;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

224;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

225;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

226;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

227;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

228;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

229;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

230;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

231;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

232;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

233;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

234;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

235;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

236;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

237;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

238;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

239;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

240;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

241;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

242;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

243;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

244;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

245;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

246;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

247;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

248;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

249;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

250;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

251;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

252;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

253;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

254;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

255;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

256;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

257;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

258;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

259;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

260;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

261;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

262;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

263;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

264;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

265;

or (c) a VH domain as in (a) and a VL domain as in (b);

or

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

637;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

638;

or (c) a VH domain as in (a) and a VL domain as in (b).

3. The bispecific antibody of claim 2, wherein the first binding domain comprises a VH domain comprising an amino acid sequence of SEQ ID NO:

266 and a VL domain comprising an amino acid sequence of SEQ ID NO;

267, and

the second binding domain comprises;

a VH domain comprising an amino acid sequence of SEQ ID NO;

184 and a VL domain comprising an amino acid sequence of SEQ ID NO;

185;

a VH domain comprising an amino acid sequence of SEQ ID NO;

186 and a VL domain comprising an amino acid sequence of SEQ ID NO;

187;

a VH domain comprising an amino acid sequence of SEQ ID NO;

214 and a VL domain comprising an amino acid sequence of SEQ ID NO;

215;

a VH domain comprising an amino acid sequence of SEQ ID NO;

216 and a VL domain comprising an amino acid sequence of SEQ ID NO;

217;

a VH domain comprising an amino acid sequence of SEQ ID NO;

218 and a VL domain comprising an amino acid sequence of SEQ ID NO;

219;

a VH domain comprising an amino acid sequence of SEQ ID NO;

220 and a VL domain comprising an amino acid sequence of SEQ ID NO;

221;

a VH domain comprising an amino acid sequence of SEQ ID NO;

222 and a VL domain comprising an amino acid sequence of SEQ ID NO;

223;

a VH domain comprising an amino acid sequence of SEQ ID NO;

224 and a VL domain comprising an amino acid sequence of SEQ ID NO;

225;

a VH domain comprising an amino acid sequence of SEQ ID NO;

226 and a VL domain comprising an amino acid sequence of SEQ ID NO;

227;

a VH domain comprising an amino acid sequence of SEQ ID NO;

228 and a VL domain comprising an amino acid sequence of SEQ ID NO;

229;

a VH domain comprising an amino acid sequence of SEQ ID NO;

230 and a VL domain comprising an amino acid sequence of SEQ ID NO;

231;

a VH domain comprising an amino acid sequence of SEQ ID NO;

232 and a VL domain comprising an amino acid sequence of SEQ ID NO;

233;

a VH domain comprising an amino acid sequence of SEQ ID NO;

234 and a VL domain comprising an amino acid sequence of SEQ ID NO;

235;

a VH domain comprising an amino acid sequence of SEQ ID NO;

236 and a VL domain comprising an amino acid sequence of SEQ ID NO;

237;

a VH domain comprising an amino acid sequence of SEQ ID NO;

238 and a VL domain comprising an amino acid sequence of SEQ ID NO;

239;

a VH domain comprising an amino acid sequence of SEQ ID NO;

240 and a VL domain comprising an amino acid sequence of SEQ ID NO;

241;

a VH domain comprising an amino acid sequence of SEQ ID NO;

242 and a VL domain comprising an amino acid sequence of SEQ ID NO;

243;

a VH domain comprising an amino acid sequence of SEQ ID NO;

244 and a VL domain comprising an amino acid sequence of SEQ ID NO;

245;

a VH domain comprising an amino acid sequence of SEQ ID NO;

246 and a VL domain comprising an amino acid sequence of SEQ ID NO;

247;

a VH domain comprising an amino acid sequence of SEQ ID NO;

248 and a VL domain comprising an amino acid sequence of SEQ ID NO;

249;

a VH domain comprising an amino acid sequence of SEQ ID NO;

250 and a VL domain comprising an amino acid sequence of SEQ ID NO;

251;

a VH domain comprising an amino acid sequence of SEQ ID NO;

252 and a VL domain comprising an amino acid sequence of SEQ ID NO;

253;

a VH domain comprising an amino acid sequence of SEQ ID NO;

254 and a VL domain comprising an amino acid sequence of SEQ ID NO;

255;

a VH domain comprising an amino acid sequence of SEQ ID NO;

256 and a VL domain comprising an amino acid sequence of SEQ ID NO;

257;

a VH domain comprising an amino acid sequence of SEQ ID NO;

258 and a VL domain comprising an amino acid sequence of SEQ ID NO;

259;

a VH domain comprising an amino acid sequence of SEQ ID NO;

260 and a VL domain comprising an amino acid sequence of SEQ ID NO;

261;

a VH domain comprising an amino acid sequence of SEQ ID NO;

262 and a VL domain comprising an amino acid sequence of SEQ ID NO;

263;

a VH domain comprising an amino acid sequence of SEQ ID NO;

264 and a VL domain comprising an amino acid sequence of SEQ ID NO;

265;

or

a VH domain comprising an amino acid sequence of SEQ ID NO;

637 and a VL domain comprising an amino acid sequence of SEQ ID NO;

638.

4. The bispecific antibody of claim 1, wherein the second binding domain comprises an HVR-H1, an HVR-H2, an HVR-H3, an HVR-L1, an HVR-L2, and an HVR-L3 comprising the amino acid sequences of SEQ ID NOs:

7-12;

SEQ ID NOs;

7, 8, 13, 10, 11, and 12;

SEQ ID NOs;

7-11 and 14;

SEQ ID NOs;

7-11 and 15;

SEQ ID NOs;

7-11 and 16;

SEQ ID NOs;

7, 8, 17, and 10-12;

SEQ ID NOs;

7, 8, 19, and 10-12;

SEQ ID NOs;

7, 8, 20, and 10-12;

or SEQ ID NOs;

7, 8, 21, 10, 11, and 22, respectively.

5. The bispecific antibody of claim 4, wherein the first binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:

266;

(b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

267;

or (c) a VH domain as in (a) and a VL domain as in (b), and

the second binding domain comprises;

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

188;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

189;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

190;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

191;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

192;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

193;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

194;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

195;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

196;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

197;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

198;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

199;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

200;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

201;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

202;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

203;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

204;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

205;

or (c) a VH domain as in (a) and a VL domain as in (b);

or

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

206;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

207;

or (c) a VH domain as in (a) and a VL domain as in (b).

6. The bispecific antibody of claim 5, wherein the first binding domain comprises a VH domain comprising an amino acid sequence of SEQ ID NO:

266 and a VL domain comprising an amino acid sequence of SEQ ID NO;

267, and

the second binding domain comprises;

a VH domain comprising an amino acid sequence of SEQ ID NO;

188 and a VL domain comprising an amino acid sequence of SEQ ID NO;

189;

a VH domain comprising an amino acid sequence of SEQ ID NO;

190 and a VL domain comprising an amino acid sequence of SEQ ID NO;

191;

a VH domain comprising an amino acid sequence of SEQ ID NO;

192 and a VL domain comprising an amino acid sequence of SEQ ID NO;

193;

a VH domain comprising an amino acid sequence of SEQ ID NO;

194 and a VL domain comprising an amino acid sequence of SEQ ID NO;

195;

a VH domain comprising an amino acid sequence of SEQ ID NO;

196 and a VL domain comprising an amino acid sequence of SEQ ID NO;

197;

a VH domain comprising an amino acid sequence of SEQ ID NO;

198 and a VL domain comprising an amino acid sequence of SEQ ID NO;

199;

a VH domain comprising an amino acid sequence of SEQ ID NO;

200 and a VL domain comprising an amino acid sequence of SEQ ID NO;

201;

a VH domain comprising an amino acid sequence of SEQ ID NO;

202 and a VL domain comprising an amino acid sequence of SEQ ID NO;

203;

a VH domain comprising an amino acid sequence of SEQ ID NO;

204 and a VL domain comprising an amino acid sequence of SEQ ID NO;

205;

or

a VH domain comprising an amino acid sequence of SEQ ID NO;

206 and a VL domain comprising an amino acid sequence of SEQ ID NO;

207.

7. The bispecific antibody of claim 1, wherein the second binding domain comprises an HVR-H1, an HVR-H2, an HVR-H3, an HVR-L1, an HVR-L2, and an HVR-L3 comprising the amino acid sequences of SEQ ID NOs:

23-28;

SEQ ID NOs;

23, 29, and 25-28;

SEQ ID NOs;

23, 30, and 25-28, respectively.

8. The bispecific antibody of claim 7, wherein the first binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:

266;

(b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

267;

or (c) a VH domain as in (a) and a VL domain as in (b), and

the second binding domain comprises;

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

208;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

209;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

210;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

211;

or (c) a VH domain as in (a) and a VL domain as in (b);

or

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

212;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

213;

or (c) a VH domain as in (a) and a VL domain as in (b).

9. The bispecific antibody of claim 8, wherein the first binding domain comprises a VH domain comprising an amino acid sequence of SEQ ID NO:

266 and a VL domain comprising an amino acid sequence of SEQ ID NO;

267, and

the second binding domain comprises;

a VH domain comprising an amino acid sequence of SEQ ID NO;

208 and a VL domain comprising an amino acid sequence of SEQ ID NO;

209;

a VH domain comprising an amino acid sequence of SEQ ID NO;

210 and a VL domain comprising an amino acid sequence of SEQ ID NO;

211;

or

a VH domain comprising an amino acid sequence of SEQ ID NO;

212 and a VL domain comprising an amino acid sequence of SEQ ID NO;

213.

37. The bispecific antibody of any one of claims 1, 10, 19, and 28, wherein the bispecific antibody binds to an epitope on CD3 comprising amino acid residue Glu6 of CD3.

47. The bispecific antibody of any one of claims 1, 10, 19, and 28, wherein the second binding domain binds to a human CD3 polypeptide or a cynomolgus monkey (cyno) CD3 polypeptide.

48. The bispecific antibody of claim 47, wherein the human CD3 polypeptide or the cyno CD3 polypeptide is a human CD3ε

polypeptide or a cyno CD3ε

polypeptide, respectively.

49. The bispecific antibody of claim 48, wherein the bispecific antibody binds the human CD3ε

polypeptide with a Kd of 250 nM or lower.

50. The bispecific antibody of any one of claims 1, 10, 19, and 28, wherein the bispecific antibody comprises an aglycosylation site mutation.

51. The bispecific antibody of claim 50, wherein the aglycosylation site mutation reduces effector function of the bispecific antibody.

52. The bispecific antibody of claim 50, wherein the aglycosylation site mutation is a substitution mutation.

53. The bispecific antibody of claim 52, wherein the bispecific antibody comprises a substitution mutation in the Fc region that reduces effector function.

54. The bispecific antibody of claim 53, wherein the substitution mutation is at amino acid residue N297, L234, L235, and/or D265 (EU numbering).

55. The bispecific antibody of claim 54, wherein the substitution mutation is selected from the group consisting of N297G, N297A, L234A, L235A, D265A, and P329G.

56. The bispecific antibody of any one of claims 1, 10, 19, and 28, wherein the bispecific antibody is monoclonal, human, humanized, or chimeric.

57. The bispecific antibody of claim 56, wherein the bispecific antibody is an antibody fragment that binds CD20 and CD3;

HER2 and CD3;

FcRH5 and CD3;

or LYPD1 and CD3.

58. The bispecific antibody of claim 57, wherein the antibody fragment is selected from the group consisting of Fab, Fab′

-SH, Fv, scFv, and (Fab′

)₂ fragments.

59. The bispecific antibody of claim 56, wherein the bispecific antibody is a full-length antibody.

60. The bispecific antibody of any one of claims 1, 10, 19, and 28, wherein the bispecific antibody is an IgG antibody.

61. The bispecific antibody of any one of claims 1, 10, 19, and 28, wherein the bispecific antibody comprises one or more heavy chain constant domains, wherein the one or more heavy chain constant domains are selected from a first CH1 (CH1₁) domain, a first CH2 (CH2₁) domain, a first CH3 (CH3₁) domain, a second CH1 (CH1₂) domain, second CH2 (CH2₂) domain, and a second CH3 (CH3₂) domain.

62. The bispecific antibody of claim 61, wherein at least one of the one or more heavy chain constant domains is paired with another heavy chain constant domain.

63. The bispecific antibody of claim 62, wherein the CH3₁ and CH3₂ domains each comprise a protuberance or cavity, and wherein the protuberance or cavity in the CH3₁ domain is positionable in the cavity or protuberance, respectively, in the CH3₂ domain.

64. The bispecific antibody of claim 63, wherein the CH3₁ and CH3₂ domains meet at an interface between said protuberance and cavity.

65. The bispecific antibody of claim 64, wherein the CH2₁ and CH2₂ domains each comprise a protuberance or cavity, and wherein the protuberance or cavity in the CH2₁ domain is positionable in the cavity or protuberance, respectively, in the CH2₂ domain.

66. The bispecific antibody of claim 65, wherein the CH2₁ and CH2₂ domains meet at an interface between said protuberance and cavity.

67. An isolated nucleic acid encoding the bispecific antibody of any one of claims 1, 10, 19, and 28.

68. A vector comprising the isolated nucleic acid of claim 67.

69. A host cell comprising the vector of claim 68.

70. A method of producing the bispecific antibody of any one of claims 1, 10, 19, and 28, the method comprising culturing the host cell of claim 65 in a culture medium.

71. An immunoconjugate comprising the bispecific antibody of any one of claims 1, 10, 19, and 28 and a cytotoxic agent.

72. A composition comprising the bispecific antibody of any one of claims 1, 10, 19, and 28.

73. A method of treating or delaying the progression of a cell proliferative disorder or an autoimmune disorder in a subject, the method comprising administering to the subject an effective amount of the bispecific antibody of any one of claims 1, 10, 19, and 28.

74. The method of claim 73, wherein the cell proliferative disorder is a cancer.

75. A method of enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder, the method comprising administering to the subject an effective amount of the bispecific antibody of any one of claims 1, 10, 19, and 28.

76. The method of claim 75, wherein the cell proliferative disorder is a cancer.

77. The method of claim 74 or 76, wherein the cancer is selected from the group consisting of breast cancer, colorectal cancer, non-small cell lung cancer, non-Hodgkin'"'"'s lymphoma (NHL), B cell lymphoma, B cell leukemia, multiple myeloma, renal cancer, prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, mesothelioma, glioblastoma, germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), Burkitt'"'"'s lymphoma (BL), B-cell prolymphocytic leukemia, Splenic marginal zone lymphoma, Hairy cell leukemia, Splenic lymphoma/leukemia, unclassifiable, Splenic diffuse red pulp small B-cell lymphoma, Hairy cell leukemia variant, Waldenströ

m macroglobulinemia, Heavy chain diseases, α

Heavy chain disease, γ

Heavy chain disease, μ

Heavy chain disease, Plasma cell myeloma, Solitary plasmacytoma of bone, Extraosseous plasmacytoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Nodal marginal zone lymphoma, Pediatric nodal marginal zone lymphoma, Pediatric follicular lymphoma, Primary cutaneous follicle centre lymphoma, T-cell/histiocyte rich large B-cell lymphoma, Primary DLBCL of the CNS, Primary cutaneous DLBCL, leg type, EBV-positive DLBCL of the elderly, DLBCL associated with chronic inflammation, Lymphomatoid granulomatosis, Primary mediastinal (thymic) large B-cell lymphoma, Intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, Plasmablastic lymphoma, Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, Primary effusion lymphoma;

B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma.

78. The method of claim 77, wherein the bispecific antibody of claim 1 is administered to a subject having a cancer selected from the group comprising germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), and Burkitt'"'"'s lymphoma (BL).

79. The method of claim 73 or 75, wherein the autoimmune disorder is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE), Wegener'"'"'s disease, inflammatory bowel disease, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, multiple sclerosis, psoriasis, IgA nephropathy, IgM polyneuropathies, myasthenia gravis, vasculitis, diabetes mellitus, Reynaud'"'"'s syndrome, Sjorgen'"'"'s syndrome, glomerulonephritis, Neuromyelitis Optica (NMO) and IgG neuropathy.

80. The method of claim 73 or 75, wherein the bispecific antibody binds to (a) a CD3 molecule located on an immune effector cell and (b) a second biological molecule located on a target cell other than the immune effector cell.

81. The method of claim 80, wherein the bispecific antibody activates the immune effector cell following binding to (a) and (b).

82. The method of claim 81, wherein the activated immune effector cell is capable of exerting a cytotoxic effect and/or an apoptotic effect on the target cell.

83. The method of claim 73 or 75, wherein the bispecific antibody is administered to the subject in a dosage of about 0.01 mg/kg to about 10 mg/kg.

84. The method of claim 73 or 75, further comprising administering to the subject a PD-1 axis binding antagonist and/or an additional therapeutic agent.

85. The method of claim 84, wherein the PD-1 axis binding antagonist or additional therapeutic agent is administered prior to, concurrently with, or subsequent to the administration of the bispecific antibody.

86. The method of claim 85, wherein the PD-1 axis binding antagonist is selected from the group consisting of a PD-1 binding antagonist, a PD-L1 binding antagonist, and a PD-L2 binding antagonist.

87. The method of claim 73 or 75, further comprising administering to the subject a glucocorticoid, rituximab, obinutuzumab, and/or an antibody-drug conjugate (ADC).

88. A kit comprising:

(a) the composition of claim 72; and

(b) a package insert comprising instructions for administering the composition to a subject to treat or delay progression of a cell proliferative disorder or an autoimmune disorder.

10. A bispecific antibody that binds to HER2 and CD3, wherein the bispecific antibody comprises an anti-HER2 arm comprising a first binding domain comprising the following six hypervariable regions (HVRs):

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO;

169;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO;

170;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO;

171;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO;

172;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO;

173; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO;

174; and

an anti-CD3 arm comprising a second binding domain comprising the amino acid sequences of any one of the following six HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3, respectively;

SEQ ID NOs;

1-6;

SEQ ID NOs;

7, 8, 181, 10, 11, and 182;

SEQ ID NOs;

23, 183, 25, 26, 27, and 28;

SEQ ID NOs;

31-36;

SEQ ID NOs;

37-42;

SEQ ID NOs;

43-48;

SEQ ID NOs;

49-54;

SEQ ID NOs;

55-60;

SEQ ID NOs;

61-66;

SEQ ID NOs;

67-72;

SEQ ID NOs;

73-78;

SEQ ID NOs;

79-84;

SEQ ID NOs;

85-90;

SEQ ID NOs;

91-96;

SEQ ID NOs;

97-102;

SEQ ID NOs;

103-108;

SEQ ID NOs;

109-114;

SEQ ID NOs;

115-120;

SEQ ID NOs;

121-126;

SEQ ID NOs;

127-132;

SEQ ID NOs;

133-138;

SEQ ID NOs;

139-144;

SEQ ID NOs;

145-150;

SEQ ID NOs;

151-156;

or

SEQ ID NOs 631-636.

11. The bispecific antibody of claim 10, wherein the first binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:

270;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

271;

or (c) a VH domain as in (a) and a VL domain as in (b), and

the second binding domain comprises;

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

184;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

185;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

186;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

187;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

214;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

215;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

216;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

217;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

218;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

219;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

220;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

221;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

222;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

223;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

224;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

225;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

226;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

227;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

228;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

229;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

230;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

231;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

232;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

233;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

234;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

235;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

236;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

237;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

238;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

239;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

240;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

241;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

242;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

243;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

244;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

245;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

246;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

247;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

248;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

249;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

250;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

251;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

252;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

253;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

254;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

255;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

256;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

257;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

258;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

259;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

260;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

261;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

262;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

263;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

264;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

265;

or (c) a VH domain as in (a) and a VL domain as in (b);

or

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

637;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

638;

or (c) a VH domain as in (a) and a VL domain as in (b).

12. The bispecific antibody of claim 11, wherein the first binding domain comprises a VH domain comprising an amino acid sequence of SEQ ID NO:

270 and a VL domain comprising an amino acid sequence of SEQ ID NO;

271, and

the second binding domain comprises;

a VH domain comprising an amino acid sequence of SEQ ID NO;

184 and a VL domain comprising an amino acid sequence of SEQ ID NO;

185;

a VH domain comprising an amino acid sequence of SEQ ID NO;

186 and a VL domain comprising an amino acid sequence of SEQ ID NO;

187;

a VH domain comprising an amino acid sequence of SEQ ID NO;

214 and a VL domain comprising an amino acid sequence of SEQ ID NO;

215;

a VH domain comprising an amino acid sequence of SEQ ID NO;

216 and a VL domain comprising an amino acid sequence of SEQ ID NO;

217;

a VH domain comprising an amino acid sequence of SEQ ID NO;

218 and a VL domain comprising an amino acid sequence of SEQ ID NO;

219;

a VH domain comprising an amino acid sequence of SEQ ID NO;

220 and a VL domain comprising an amino acid sequence of SEQ ID NO;

221;

a VH domain comprising an amino acid sequence of SEQ ID NO;

222 and a VL domain comprising an amino acid sequence of SEQ ID NO;

223;

a VH domain comprising an amino acid sequence of SEQ ID NO;

224 and a VL domain comprising an amino acid sequence of SEQ ID NO;

225;

a VH domain comprising an amino acid sequence of SEQ ID NO;

226 and a VL domain comprising an amino acid sequence of SEQ ID NO;

227;

a VH domain comprising an amino acid sequence of SEQ ID NO;

228 and a VL domain comprising an amino acid sequence of SEQ ID NO;

229;

a VH domain comprising an amino acid sequence of SEQ ID NO;

230 and a VL domain comprising an amino acid sequence of SEQ ID NO;

231;

a VH domain comprising an amino acid sequence of SEQ ID NO;

232 and a VL domain comprising an amino acid sequence of SEQ ID NO;

233;

a VH domain comprising an amino acid sequence of SEQ ID NO;

234 and a VL domain comprising an amino acid sequence of SEQ ID NO;

235;

a VH domain comprising an amino acid sequence of SEQ ID NO;

236 and a VL domain comprising an amino acid sequence of SEQ ID NO;

237;

a VH domain comprising an amino acid sequence of SEQ ID NO;

238 and a VL domain comprising an amino acid sequence of SEQ ID NO;

239;

a VH domain comprising an amino acid sequence of SEQ ID NO;

240 and a VL domain comprising an amino acid sequence of SEQ ID NO;

241;

a VH domain comprising an amino acid sequence of SEQ ID NO;

242 and a VL domain comprising an amino acid sequence of SEQ ID NO;

243;

a VH domain comprising an amino acid sequence of SEQ ID NO;

244 and a VL domain comprising an amino acid sequence of SEQ ID NO;

245;

a VH domain comprising an amino acid sequence of SEQ ID NO;

246 and a VL domain comprising an amino acid sequence of SEQ ID NO;

247;

a VH domain comprising an amino acid sequence of SEQ ID NO;

248 and a VL domain comprising an amino acid sequence of SEQ ID NO;

249;

a VH domain comprising an amino acid sequence of SEQ ID NO;

250 and a VL domain comprising an amino acid sequence of SEQ ID NO;

251;

a VH domain comprising an amino acid sequence of SEQ ID NO;

252 and a VL domain comprising an amino acid sequence of SEQ ID NO;

253;

a VH domain comprising an amino acid sequence of SEQ ID NO;

254 and a VL domain comprising an amino acid sequence of SEQ ID NO;

255;

a VH domain comprising an amino acid sequence of SEQ ID NO;

256 and a VL domain comprising an amino acid sequence of SEQ ID NO;

257;

a VH domain comprising an amino acid sequence of SEQ ID NO;

258 and a VL domain comprising an amino acid sequence of SEQ ID NO;

259;

a VH domain comprising an amino acid sequence of SEQ ID NO;

260 and a VL domain comprising an amino acid sequence of SEQ ID NO;

261;

a VH domain comprising an amino acid sequence of SEQ ID NO;

262 and a VL domain comprising an amino acid sequence of SEQ ID NO;

263;

a VH domain comprising an amino acid sequence of SEQ ID NO;

264 and a VL domain comprising an amino acid sequence of SEQ ID NO;

265;

or

a VH domain comprising an amino acid sequence of SEQ ID NO;

637 and a VL domain comprising an amino acid sequence of SEQ ID NO;

638.

13. The bispecific antibody of claim 10, wherein the second binding domain comprises an HVR-H1, an HVR-H2, an HVR-H3, an HVR-L1, an HVR-L2, and an HVR-L3 comprising the amino acid sequences of SEQ ID NOs:

7-12;

SEQ ID NOs;

7, 8, 13, 10, 11, and 12;

SEQ ID NOs;

7-11 and 14;

SEQ ID NOs;

7-11 and 15;

SEQ ID NOs;

7-11 and 16;

SEQ ID NOs;

7, 8, 17, and 10-12;

SEQ ID NOs;

7, 8, 19, and 10-12;

SEQ ID NOs;

7, 8, 20, and 10-12;

or SEQ ID NOs;

7, 8, 21, 10, 11, and 22, respectively.

14. The bispecific antibody of claim of claim 13, wherein the first binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:

270;

(b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

271;

or (c) a VH domain as in (a) and a VL domain as in (b), and

the second binding domain comprises;

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

188;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

189;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

190;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

191;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

192;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

193;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

194;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

195;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

196;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

197;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

198;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

199;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

200;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

201;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

202;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

203;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

204;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

205;

or (c) a VH domain as in (a) and a VL domain as in (b);

or

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

206;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

207;

or (c) a VH domain as in (a) and a VL domain as in (b).

15. The bispecific antibody of claim 14, wherein the first binding domain comprises a VH domain comprising an amino acid sequence of SEQ ID NO:

270 and a VL domain comprising an amino acid sequence of SEQ ID NO;

271, and

the second binding domain comprises;

a VH domain comprising an amino acid sequence of SEQ ID NO;

188 and a VL domain comprising an amino acid sequence of SEQ ID NO;

189;

a VH domain comprising an amino acid sequence of SEQ ID NO;

190 and a VL domain comprising an amino acid sequence of SEQ ID NO;

191;

a VH domain comprising an amino acid sequence of SEQ ID NO;

192 and a VL domain comprising an amino acid sequence of SEQ ID NO;

193;

a VH domain comprising an amino acid sequence of SEQ ID NO;

194 and a VL domain comprising an amino acid sequence of SEQ ID NO;

195;

a VH domain comprising an amino acid sequence of SEQ ID NO;

196 and a VL domain comprising an amino acid sequence of SEQ ID NO;

197;

a VH domain comprising an amino acid sequence of SEQ ID NO;

198 and a VL domain comprising an amino acid sequence of SEQ ID NO;

199;

a VH domain comprising an amino acid sequence of SEQ ID NO;

200 and a VL domain comprising an amino acid sequence of SEQ ID NO;

201;

a VH domain comprising an amino acid sequence of SEQ ID NO;

202 and a VL domain comprising an amino acid sequence of SEQ ID NO;

203;

a VH domain comprising an amino acid sequence of SEQ ID NO;

204 and a VL domain comprising an amino acid sequence of SEQ ID NO;

205;

or

a VH domain comprising an amino acid sequence of SEQ ID NO;

206 and a VL domain comprising an amino acid sequence of SEQ ID NO;

207.

16. The bispecific antibody of claim 10, wherein the second binding domain comprises an HVR-H1, an HVR-H2, an HVR-H3, an HVR-L1, an HVR-L2, and an HVR-L3 comprising the amino acid sequences of SEQ ID NOs:

23-28;

SEQ ID NOs;

23, 29, and 25-28;

SEQ ID NOs;

23, 30, and 25-28, respectively.

17. The bispecific antibody of claim 16, wherein the first binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:

270;

(b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

271;

or (c) a VH domain as in (a) and a VL domain as in (b), and

the second binding domain comprises;

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

208;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

209;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

210;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

211;

or (c) a VH domain as in (a) and a VL domain as in (b);

or

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

212;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

213;

or (c) a VH domain as in (a) and a VL domain as in (b).

18. The bispecific antibody of claim 17, wherein the first binding domain comprises a VH domain comprising an amino acid sequence of SEQ ID NO:

270 and a VL domain comprising an amino acid sequence of SEQ ID NO;

271, and

the second binding domain comprises;

a VH domain comprising an amino acid sequence of SEQ ID NO;

208 and a VL domain comprising an amino acid sequence of SEQ ID NO;

209;

a VH domain comprising an amino acid sequence of SEQ ID NO;

210 and a VL domain comprising an amino acid sequence of SEQ ID NO;

211;

or

a VH domain comprising an amino acid sequence of SEQ ID NO;

212 and a VL domain comprising an amino acid sequence of SEQ ID NO;

213.

19. A bispecific antibody that binds to FcRH5 and CD3, wherein the bispecific antibody comprises an anti-FcRH5 arm comprising a first binding domain comprising the following six hypervariable regions (HVRs):

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO;

163;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO;

164;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO;

165;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO;

166;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO;

167; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO;

168; and

an anti-CD3 arm comprising a second binding domain comprising the amino acid sequences of any one of the following six HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3, respectively;

SEQ ID NOs;

1-6;

SEQ ID NOs;

7, 8, 181, 10, 11, and 182;

SEQ ID NOs;

23, 183, 25, 26, 27, and 28;

SEQ ID NOs;

31-36;

SEQ ID NOs;

37-42;

SEQ ID NOs;

43-48;

SEQ ID NOs;

49-54;

SEQ ID NOs;

55-60;

SEQ ID NOs;

61-66;

SEQ ID NOs;

67-72;

SEQ ID NOs;

73-78;

SEQ ID NOs;

79-84;

SEQ ID NOs;

85-90;

SEQ ID NOs;

91-96;

SEQ ID NOs;

97-102;

SEQ ID NOs;

103-108;

SEQ ID NOs;

109-114;

SEQ ID NOs;

115-120;

SEQ ID NOs;

121-126;

SEQ ID NOs;

127-132;

SEQ ID NOs;

133-138;

SEQ ID NOs;

139-144;

SEQ ID NOs;

145-150;

SEQ ID NOs;

151-156;

or

SEQ ID NOs;

631-636.

20. The bispecific antibody of claim 19, wherein the first binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:

268;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

269;

or (c) a VH domain as in (a) and a VL domain as in (b), and

the second binding domain comprises;

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

184;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

185;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

186;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

187;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

214;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

215;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

216;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

217;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

218;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

219;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

220;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

221;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

222;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

223;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

224;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

225;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

226;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

227;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

228;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

229;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

230;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

231;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

232;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

233;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

234;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

235;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

236;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

237;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

238;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

239;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

240;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

241;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

242;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

243;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

244;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

245;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

246;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

247;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

248;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

249;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

250;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

251;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

252;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

253;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

254;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

255;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

256;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

257;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

258;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

259;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

260;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

261;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

262;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

263;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

264;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

265;

or (c) a VH domain as in (a) and a VL domain as in (b);

or

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

637;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

638;

or (c) a VH domain as in (a) and a VL domain as in (b).

21. The bispecific antibody of claim 20, wherein the first binding domain comprises a VH domain comprising an amino acid sequence of SEQ ID NO:

268 and a VL domain comprising an amino acid sequence of SEQ ID NO;

269, and

the second binding domain comprises;

a VH domain comprising an amino acid sequence of SEQ ID NO;

184 and a VL domain comprising an amino acid sequence of SEQ ID NO;

185;

a VH domain comprising an amino acid sequence of SEQ ID NO;

186 and a VL domain comprising an amino acid sequence of SEQ ID NO;

187;

a VH domain comprising an amino acid sequence of SEQ ID NO;

214 and a VL domain comprising an amino acid sequence of SEQ ID NO;

215;

a VH domain comprising an amino acid sequence of SEQ ID NO;

216 and a VL domain comprising an amino acid sequence of SEQ ID NO;

217;

a VH domain comprising an amino acid sequence of SEQ ID NO;

218 and a VL domain comprising an amino acid sequence of SEQ ID NO;

219;

a VH domain comprising an amino acid sequence of SEQ ID NO;

220 and a VL domain comprising an amino acid sequence of SEQ ID NO;

221;

a VH domain comprising an amino acid sequence of SEQ ID NO;

222 and a VL domain comprising an amino acid sequence of SEQ ID NO;

223;

a VH domain comprising an amino acid sequence of SEQ ID NO;

224 and a VL domain comprising an amino acid sequence of SEQ ID NO;

225;

a VH domain comprising an amino acid sequence of SEQ ID NO;

226 and a VL domain comprising an amino acid sequence of SEQ ID NO;

227;

a VH domain comprising an amino acid sequence of SEQ ID NO;

228 and a VL domain comprising an amino acid sequence of SEQ ID NO;

229;

a VH domain comprising an amino acid sequence of SEQ ID NO;

230 and a VL domain comprising an amino acid sequence of SEQ ID NO;

231;

a VH domain comprising an amino acid sequence of SEQ ID NO;

232 and a VL domain comprising an amino acid sequence of SEQ ID NO;

233;

a VH domain comprising an amino acid sequence of SEQ ID NO;

234 and a VL domain comprising an amino acid sequence of SEQ ID NO;

235;

a VH domain comprising an amino acid sequence of SEQ ID NO;

236 and a VL domain comprising an amino acid sequence of SEQ ID NO;

237;

a VH domain comprising an amino acid sequence of SEQ ID NO;

238 and a VL domain comprising an amino acid sequence of SEQ ID NO;

239;

a VH domain comprising an amino acid sequence of SEQ ID NO;

240 and a VL domain comprising an amino acid sequence of SEQ ID NO;

241;

a VH domain comprising an amino acid sequence of SEQ ID NO;

242 and a VL domain comprising an amino acid sequence of SEQ ID NO;

243;

a VH domain comprising an amino acid sequence of SEQ ID NO;

244 and a VL domain comprising an amino acid sequence of SEQ ID NO;

245;

a VH domain comprising an amino acid sequence of SEQ ID NO;

246 and a VL domain comprising an amino acid sequence of SEQ ID NO;

247;

a VH domain comprising an amino acid sequence of SEQ ID NO;

248 and a VL domain comprising an amino acid sequence of SEQ ID NO;

249;

a VH domain comprising an amino acid sequence of SEQ ID NO;

250 and a VL domain comprising an amino acid sequence of SEQ ID NO;

251;

a VH domain comprising an amino acid sequence of SEQ ID NO;

252 and a VL domain comprising an amino acid sequence of SEQ ID NO;

253;

a VH domain comprising an amino acid sequence of SEQ ID NO;

254 and a VL domain comprising an amino acid sequence of SEQ ID NO;

255;

a VH domain comprising an amino acid sequence of SEQ ID NO;

256 and a VL domain comprising an amino acid sequence of SEQ ID NO;

257;

a VH domain comprising an amino acid sequence of SEQ ID NO;

258 and a VL domain comprising an amino acid sequence of SEQ ID NO;

259;

a VH domain comprising an amino acid sequence of SEQ ID NO;

260 and a VL domain comprising an amino acid sequence of SEQ ID NO;

261;

a VH domain comprising an amino acid sequence of SEQ ID NO;

262 and a VL domain comprising an amino acid sequence of SEQ ID NO;

263;

a VH domain comprising an amino acid sequence of SEQ ID NO;

264 and a VL domain comprising an amino acid sequence of SEQ ID NO;

265;

or

a VH domain comprising an amino acid sequence of SEQ ID NO;

637 and a VL domain comprising an amino acid sequence of SEQ ID NO;

638.

22. The bispecific antibody of claim 19, wherein the second binding domain comprises an HVR-H1, an HVR-H2, an HVR-H3, an HVR-L1, an HVR-L2, and an HVR-L3 comprising the amino acid sequences of SEQ ID NOs:

7-12;

SEQ ID NOs;

7, 8, 13, 10, 11, and 12;

SEQ ID NOs;

7-11 and 14;

SEQ ID NOs;

7-11 and 15;

SEQ ID NOs;

7-11 and 16;

SEQ ID NOs;

7, 8, 17, and 10-12;

SEQ ID NOs;

7, 8, 19, and 10-12;

SEQ ID NOs;

7, 8, 20, and 10-12;

or SEQ ID NOs;

7, 8, 21, 10, 11, and 22, respectively.

23. The bispecific antibody of claim 22, wherein the first binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:

268;

(b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

269;

or (c) a VH domain as in (a) and a VL domain as in (b), and

the second binding domain comprises;

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

188;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

189;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

190;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

191;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

192;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

193;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

194;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

195;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

196;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

197;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

198;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

199;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

200;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

201;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

202;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

203;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

204;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

205;

or (c) a VH domain as in (a) and a VL domain as in (b);

or

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

206;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

207;

or (c) a VH domain as in (a) and a VL domain as in (b).

24. The bispecific antibody of claim 23, wherein the first binding domain comprises a VH domain comprising an amino acid sequence of SEQ ID NO:

268 and a VL domain comprising an amino acid sequence of SEQ ID NO;

269, and

the second binding domain comprises;

a VH domain comprising an amino acid sequence of SEQ ID NO;

188 and a VL domain comprising an amino acid sequence of SEQ ID NO;

189;

a VH domain comprising an amino acid sequence of SEQ ID NO;

190 and a VL domain comprising an amino acid sequence of SEQ ID NO;

191;

a VH domain comprising an amino acid sequence of SEQ ID NO;

192 and a VL domain comprising an amino acid sequence of SEQ ID NO;

193;

a VH domain comprising an amino acid sequence of SEQ ID NO;

194 and a VL domain comprising an amino acid sequence of SEQ ID NO;

195;

a VH domain comprising an amino acid sequence of SEQ ID NO;

196 and a VL domain comprising an amino acid sequence of SEQ ID NO;

197;

a VH domain comprising an amino acid sequence of SEQ ID NO;

198 and a VL domain comprising an amino acid sequence of SEQ ID NO;

199;

a VH domain comprising an amino acid sequence of SEQ ID NO;

200 and a VL domain comprising an amino acid sequence of SEQ ID NO;

201;

a VH domain comprising an amino acid sequence of SEQ ID NO;

202 and a VL domain comprising an amino acid sequence of SEQ ID NO;

203;

a VH domain comprising an amino acid sequence of SEQ ID NO;

204 and a VL domain comprising an amino acid sequence of SEQ ID NO;

205;

or

a VH domain comprising an amino acid sequence of SEQ ID NO;

206 and a VL domain comprising an amino acid sequence of SEQ ID NO;

207.

25. The bispecific antibody of claim 19, wherein the second binding domain comprises an HVR-H1, an HVR-H2, an HVR-H3, an HVR-L1, an HVR-L2, and an HVR-L3 comprising the amino acid sequences of SEQ ID NOs:

23-28;

SEQ ID NOs;

23, 29, and 25-28;

SEQ ID NOs;

23, 30, and 25-28, respectively.

26. The bispecific antibody of claim 25, wherein the first binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:

268;

(b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

269;

or (c) a VH domain as in (a) and a VL domain as in (b), and

the second binding domain comprises;

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

208;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

209;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

210;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

211;

or (c) a VH domain as in (a) and a VL domain as in (b);

or

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

212;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

213;

or (c) a VH domain as in (a) and a VL domain as in (b).

27. The bispecific antibody of claim 26, wherein the first binding domain comprises a VH domain comprising an amino acid sequence of SEQ ID NO:

268 and a VL domain comprising an amino acid sequence of SEQ ID NO;

269, and

the second binding domain comprises;

a VH domain comprising an amino acid sequence of SEQ ID NO;

208 and a VL domain comprising an amino acid sequence of SEQ ID NO;

209;

a VH domain comprising an amino acid sequence of SEQ ID NO;

210 and a VL domain comprising an amino acid sequence of SEQ ID NO;

211;

or

a VH domain comprising an amino acid sequence of SEQ ID NO;

212 and a VL domain comprising an amino acid sequence of SEQ ID NO;

213.

28. A bispecific antibody that binds to LYPD1 and CD3, wherein the bispecific antibody comprises an anti-LYPD1 arm comprising a first binding domain comprising the following six hypervariable regions (HVRs):

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO;

175;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO;

176;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO;

177;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO;

178;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO;

179; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO;

180; and

an anti-CD3 arm comprising a second binding domain comprising the amino acid sequences of any one of the following six HVR-H1, an HVR-H2, an HVR-H3, an HVR-L1, an HVR-L2, and an HVR-L3, respectively;

SEQ ID NOs;

1-6;

SEQ ID NOs;

7, 8, 181, 10, 11, and 182;

SEQ ID NOs;

23, 183, 25, 26, 27, and 28;

SEQ ID NOs;

31-36;

SEQ ID NOs;

37-42;

SEQ ID NOs;

43-48;

SEQ ID NOs;

49-54;

SEQ ID NOs;

55-60;

SEQ ID NOs;

61-66;

SEQ ID NOs;

67-72;

SEQ ID NOs;

73-78;

SEQ ID NOs;

79-84;

SEQ ID NOs;

85-90;

SEQ ID NOs;

91-96;

SEQ ID NOs;

97-102;

SEQ ID NOs;

103-108;

SEQ ID NOs;

109-114;

SEQ ID NOs;

115-120;

SEQ ID NOs;

121-126;

SEQ ID NOs;

127-132;

SEQ ID NOs;

133-138;

SEQ ID NOs;

139-144;

SEQ ID NOs;

145-150;

SEQ ID NOs;

151-156;

or

SEQ ID NOs;

631-636.

29. The bispecific antibody of claim 28, wherein the first binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:

272;

(b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

273;

or (c) a VH domain as in (a) and a VL domain as in (b), and

the second binding domain comprises;

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

184;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

185;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

186;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

187;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

214;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

215;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

216;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

217;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

218;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

219;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

220;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

221;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

222;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

223;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

224;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

225;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

226;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

227;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

228;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

229;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

230;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

231;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

232;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

233;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

234;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

235;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

236;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

237;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

238;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

239;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

240;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

241;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

242;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

243;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

244;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

245;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

246;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

247;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

248;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

249;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

250;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

251;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

252;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

253;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

254;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

255;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

256;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

257;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

258;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

259;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

260;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

261;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

262;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

263;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

264;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

265;

or (c) a VH domain as in (a) and a VL domain as in (b);

or

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

637;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

638;

or (c) a VH domain as in (a) and a VL domain as in (b).

30. The bispecific antibody of claim 29, wherein the first binding domain comprises a VH domain comprising an amino acid sequence of SEQ ID NO:

272 and a VL domain comprising an amino acid sequence of SEQ ID NO;

273, and

the second binding domain comprises;

a VH domain comprising an amino acid sequence of SEQ ID NO;

184 and a VL domain comprising an amino acid sequence of SEQ ID NO;

185;

a VH domain comprising an amino acid sequence of SEQ ID NO;

186 and a VL domain comprising an amino acid sequence of SEQ ID NO;

187;

a VH domain comprising an amino acid sequence of SEQ ID NO;

214 and a VL domain comprising an amino acid sequence of SEQ ID NO;

215;

a VH domain comprising an amino acid sequence of SEQ ID NO;

216 and a VL domain comprising an amino acid sequence of SEQ ID NO;

217;

a VH domain comprising an amino acid sequence of SEQ ID NO;

218 and a VL domain comprising an amino acid sequence of SEQ ID NO;

219;

a VH domain comprising an amino acid sequence of SEQ ID NO;

220 and a VL domain comprising an amino acid sequence of SEQ ID NO;

221;

a VH domain comprising an amino acid sequence of SEQ ID NO;

222 and a VL domain comprising an amino acid sequence of SEQ ID NO;

223;

a VH domain comprising an amino acid sequence of SEQ ID NO;

224 and a VL domain comprising an amino acid sequence of SEQ ID NO;

225;

a VH domain comprising an amino acid sequence of SEQ ID NO;

226 and a VL domain comprising an amino acid sequence of SEQ ID NO;

227;

a VH domain comprising an amino acid sequence of SEQ ID NO;

228 and a VL domain comprising an amino acid sequence of SEQ ID NO;

229;

a VH domain comprising an amino acid sequence of SEQ ID NO;

230 and a VL domain comprising an amino acid sequence of SEQ ID NO;

231;

a VH domain comprising an amino acid sequence of SEQ ID NO;

232 and a VL domain comprising an amino acid sequence of SEQ ID NO;

233;

a VH domain comprising an amino acid sequence of SEQ ID NO;

234 and a VL domain comprising an amino acid sequence of SEQ ID NO;

235;

a VH domain comprising an amino acid sequence of SEQ ID NO;

236 and a VL domain comprising an amino acid sequence of SEQ ID NO;

237;

a VH domain comprising an amino acid sequence of SEQ ID NO;

238 and a VL domain comprising an amino acid sequence of SEQ ID NO;

239;

a VH domain comprising an amino acid sequence of SEQ ID NO;

240 and a VL domain comprising an amino acid sequence of SEQ ID NO;

241;

a VH domain comprising an amino acid sequence of SEQ ID NO;

242 and a VL domain comprising an amino acid sequence of SEQ ID NO;

243;

a VH domain comprising an amino acid sequence of SEQ ID NO;

244 and a VL domain comprising an amino acid sequence of SEQ ID NO;

245;

a VH domain comprising an amino acid sequence of SEQ ID NO;

246 and a VL domain comprising an amino acid sequence of SEQ ID NO;

247;

a VH domain comprising an amino acid sequence of SEQ ID NO;

248 and a VL domain comprising an amino acid sequence of SEQ ID NO;

249;

a VH domain comprising an amino acid sequence of SEQ ID NO;

250 and a VL domain comprising an amino acid sequence of SEQ ID NO;

251;

a VH domain comprising an amino acid sequence of SEQ ID NO;

252 and a VL domain comprising an amino acid sequence of SEQ ID NO;

253;

a VH domain comprising an amino acid sequence of SEQ ID NO;

254 and a VL domain comprising an amino acid sequence of SEQ ID NO;

255;

a VH domain comprising an amino acid sequence of SEQ ID NO;

256 and a VL domain comprising an amino acid sequence of SEQ ID NO;

257;

a VH domain comprising an amino acid sequence of SEQ ID NO;

258 and a VL domain comprising an amino acid sequence of SEQ ID NO;

259;

a VH domain comprising an amino acid sequence of SEQ ID NO;

260 and a VL domain comprising an amino acid sequence of SEQ ID NO;

261;

a VH domain comprising an amino acid sequence of SEQ ID NO;

262 and a VL domain comprising an amino acid sequence of SEQ ID NO;

263;

a VH domain comprising an amino acid sequence of SEQ ID NO;

264 and a VL domain comprising an amino acid sequence of SEQ ID NO;

265;

or

a VH domain comprising an amino acid sequence of SEQ ID NO;

637 and a VL domain comprising an amino acid sequence of SEQ ID NO;

638.

31. The bispecific antibody of claim 28, wherein the second binding domain comprises an HVR-H1, an HVR-H2, an HVR-H3, an HVR-L1, an HVR-L2, and an HVR-L3 comprising the amino acid sequences of SEQ ID NOs:

7-12;

SEQ ID NOs;

7, 8, 13, 10, 11, and 12;

SEQ ID NOs;

7-11 and 14;

SEQ ID NOs;

7-11 and 15;

SEQ ID NOs;

7-11 and 16;

SEQ ID NOs;

7, 8, 17, and 10-12;

SEQ ID NOs;

7, 8, 19, and 10-12;

SEQ ID NOs;

7, 8, 20, and 10-12;

or SEQ ID NOs;

7, 8, 21, 10, 11, and 22, respectively.

32. The bispecific antibody of claim 31, wherein the first binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:

272;

(b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

273;

or (c) a VH domain as in (a) and a VL domain as in (b), and

the second binding domain comprises;

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

188;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

189;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

190;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

191;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

192;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

193;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

194;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

195;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

196;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

197;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

198;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

199;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

200;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

201;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

202;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

203;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

204;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

205;

or (c) a VH domain as in (a) and a VL domain as in (b);

or

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

206;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

207;

or (c) a VH domain as in (a) and a VL domain as in (b).

33. The bispecific antibody of claim 32, wherein the first binding domain comprises a VH domain comprising an amino acid sequence of SEQ ID NO:

272 and a VL domain comprising an amino acid sequence of SEQ ID NO;

273, and

the second binding domain comprises;

a VH domain comprising an amino acid sequence of SEQ ID NO;

188 and a VL domain comprising an amino acid sequence of SEQ ID NO;

189;

a VH domain comprising an amino acid sequence of SEQ ID NO;

190 and a VL domain comprising an amino acid sequence of SEQ ID NO;

191;

a VH domain comprising an amino acid sequence of SEQ ID NO;

192 and a VL domain comprising an amino acid sequence of SEQ ID NO;

193;

a VH domain comprising an amino acid sequence of SEQ ID NO;

194 and a VL domain comprising an amino acid sequence of SEQ ID NO;

195;

a VH domain comprising an amino acid sequence of SEQ ID NO;

196 and a VL domain comprising an amino acid sequence of SEQ ID NO;

197;

a VH domain comprising an amino acid sequence of SEQ ID NO;

198 and a VL domain comprising an amino acid sequence of SEQ ID NO;

199;

a VH domain comprising an amino acid sequence of SEQ ID NO;

200 and a VL domain comprising an amino acid sequence of SEQ ID NO;

201;

a VH domain comprising an amino acid sequence of SEQ ID NO;

202 and a VL domain comprising an amino acid sequence of SEQ ID NO;

203;

a VH domain comprising an amino acid sequence of SEQ ID NO;

204 and a VL domain comprising an amino acid sequence of SEQ ID NO;

205;

or

a VH domain comprising an amino acid sequence of SEQ ID NO;

206 and a VL domain comprising an amino acid sequence of SEQ ID NO;

207.

34. The bispecific antibody of claim 28, wherein the second binding domain comprises an HVR-H1, an HVR-H2, an HVR-H3, an HVR-L1, an HVR-L2, and an HVR-L3 comprising the amino acid sequences of SEQ ID NOs:

23-28;

SEQ ID NOs;

23, 29, and 25-28;

SEQ ID NOs;

23, 30, and 25-28, respectively.

35. The bispecific antibody of claim 34, wherein the first binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:

272;

(b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

273;

or (c) a VH domain as in (a) and a VL domain as in (b), and

the second binding domain comprises;

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

208;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

209;

or (c) a VH domain as in (a) and a VL domain as in (b);

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

210;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

211;

or (c) a VH domain as in (a) and a VL domain as in (b);

or

(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

212;

(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO;

213;

or (c) a VH domain as in (a) and a VL domain as in (b).

36. The bispecific antibody of claim 35, wherein the first binding domain comprises a VH domain comprising an amino acid sequence of SEQ ID NO:

272 and a VL domain comprising an amino acid sequence of SEQ ID NO;

273, and

the second binding domain comprises;

a VH domain comprising an amino acid sequence of SEQ ID NO;

208 and a VL domain comprising an amino acid sequence of SEQ ID NO;

209;

a VH domain comprising an amino acid sequence of SEQ ID NO;

210 and a VL domain comprising an amino acid sequence of SEQ ID NO;

211;

or

a VH domain comprising an amino acid sequence of SEQ ID NO;

212 and a VL domain comprising an amino acid sequence of SEQ ID NO;

213.

38. A bispecific antibody that binds to CD20 and CD3, wherein the bispecific antibody comprises an anti-CD20 arm comprising a first binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO;

157;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO;

158;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO;

159;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO;

160;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO;

161; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO;

162; and

an anti-CD3 arm which binds to an epitope on CD3 comprising amino acid residue Glu6.

42. The bispecific antibody of any one of claims 38-41, wherein the epitope further comprises one or more additional amino acid residues selected from the group consisting of Gln1, Asp2, and Met7 of CD3.

43. The bispecific antibody of any one of claims 38-41, wherein the epitope comprises amino acid residues Gln1, Asp2, and Glu6 of CD3.

44. The bispecific antibody of claim 43, wherein the epitope comprises amino acid residues Gln1, Asp2, Glu6, and Met7 of CD3.

45. The bispecific antibody of any of claims 38-41, wherein the epitope does not comprise amino acid residue Glu5 of CD3.

46. The bispecific antibody of claim 45, wherein the epitope does not comprise amino acid residues Gly3 and Glu5 of CD3.

39. A bispecific antibody that binds to HER2 and CD3, wherein the bispecific antibody comprises an anti-HER2 arm comprising a first binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO;

169;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO;

170;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO;

171;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO;

172;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO;

173; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO;

174; and

an anti-CD3 arm which binds to an epitope on CD3 comprising amino acid residue Glu6.

40. A bispecific antibody that binds to FcRH5 and CD3, wherein the bispecific antibody comprises an anti-FcRH5 arm comprising a first binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO;

163;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO;

164;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO;

165;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO;

166;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO;

167; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO;

168; and

an anti-CD3 arm which binds to an epitope on CD3 comprising amino acid residue Glu6.

41. A bispecific antibody that binds to LYPD1 and CD3, wherein the bispecific antibody comprises an anti-LYPD1 arm comprising a first binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO;

175;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO;

176;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO;

177;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO;

178;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO;

179; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO;

180; and

an anti-CD3 arm which binds to an epitope on CD3 comprising amino acid residue Glu6.